Drug Approval | March 17, 2022
Lynparza reduced risk of death by 32% in the adjuvant treatment of patients with breast cancer
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
Since 1993, Beghou Consulting has helped life sciences companies - especially emerging pharmaceutical companies - establish and manage commercial operations to better market and sell therapies
If the government feels that the industry is not complying with the uniform code, it will consider making it a statutory code
According to the Indian Council of Medical Research (ICMR), there will be an estimated 12 % rise in cancer cases in India in the next five years
This pre-packaged release is a ready-to-go solution with powerful, straightforward bioanalysis pipeline support
The meeting was co-organized by World Health Organization’s Country Office for India, World Animal Protection India and ReAct Asia Pacific
The investment will accelerate the overall Sarclisa development program
Career achievement for contributions in Physiologically based pharmacokinetic (PBPK) and biologically based does response (BBDR) modelling tools
OCE+ uses IQVIA’s industry-leading data and advanced analytics to deliver AI-driven recommendations directly into the daily workflows of life sciences commercial teams
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
Subscribe To Our Newsletter & Stay Updated
